^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CD19CAR/virus specific T cell therapy

    i
    Other names: CD19CAR/virus specific T cell therapy, CD19CAR/virus specific T cells, CD19 chimeric receptor trivirus specific T cells, CD19.CAR-multiVST, multi-virus specific cytotoxic T lymphocytes expressing CD19 chimeric receptors
    Associations

    News

    Trials
    Company:
    Baylor College of Medicine
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    over2years
    CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) (clinicaltrials.gov)
    P1, N=0, Withdrawn, Baylor College of Medicine | N=34 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    CD19CAR/virus specific T cell therapy
    almost4years
    CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) (clinicaltrials.gov)
    P1, N=34, Not yet recruiting, Baylor College of Medicine | Trial completion date: Jan 2039 --> Aug 2040 | Trial primary completion date: Jan 2024 --> Aug 2025
    Clinical • Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    CD19CAR/virus specific T cell therapy
    4years
    CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) (clinicaltrials.gov)
    P1, N=34, Not yet recruiting, Baylor College of Medicine | Trial completion date: Aug 2038 --> Jan 2039 | Trial primary completion date: Aug 2023 --> Jan 2024
    Clinical • Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    CD19CAR/virus specific T cell therapy